Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis.

07:00 EST 26th November 2018 | BioPortfolio

Summary of "Factors Associated With Cysticidal Treatment Response in Extraparenchymal Neurocysticercosis."

Extraparenchymal neurocysticercosis is the most severe form of cysticercosis, and response to treatment is suboptimal. We sought to determine how demographic and clinical characteristics and albendazole sulfoxide concentrations were related to cysticidal treatment response. We conducted a longitudinal study of 31 participants with extraparenchymal vesicular parasites who received the same treatment, albendazole 30 mg/kg/day for 10 days with dexamethasone 0.4 mg/kg/day for 13 days, followed by a prednisone taper. Response to treatment was determined by parasite volumes before and 6 months after treatment. Eight participants (25.8%) had a complete treatment response, 16 (51.6%) had a treatment response > 50% but < 100%, and 7 (22.6%) had a treatment response < 50%. Complete treatment response was significantly associated with higher concentrations of albendazole sulfoxide (P = .032), younger age (P = .032), fewer cysts (P = .049) and lower pretreatment parasite volume (P = .037). Higher number of previous cysticidal treatment courses was associated with a noncomplete treatment response (P = .023). Although the large proportion of participants with less than a complete response emphasizes the need to develop more efficacious pharmacologic regimens, the association of albendazole sulfoxide concentrations with treatment response highlights the importance of optimizing existing therapeutic regimens. In addition, the association of treatment response with parasite volume emphasizes the importance of early diagnosis.


Journal Details

This article was published in the following journal.

Name: Journal of clinical pharmacology
ISSN: 1552-4604


DeepDyve research library

PubMed Articles [32429 Associated PubMed Articles listed on BioPortfolio]

Neurocysticercosis and epilepsy in sub-Saharan Africa.

Neurocysticercosis is a public health problem and the leading cause of epilepsy in developing countries especially in sub-Saharan Africa (SSA). In this paper, the authors review the epidemiology of cy...

The genetic factors of non-response to anti-vascular endothelial growth factor therapy.

The response to anti-vascular endothelial growth factor (VEGF) treatment is variable. It is generally measured in terms of changes in correlated functional and/or anatomical outcomes, and patients are...

Endoscopic route for excision of intraventricular Neurocysticercosis: Light at the end of the tunnel.

Poor sanitation, hygiene and archaic cooking practises have lead to Neurocysticercosis being endemic in India. Apart from a cortical location that leads to seizures, intraventricular NCC's can present...

Analysis of factors relevant to primary non-response to infliximab treatment in patients with Crohn's disease.

To evaluate factors relevant to primary non-response in patients with Crohn's disease undergoing infliximab (IFX) treatment at week 14. Patients with Crohn's disease in the Third Hospital of Peking U...

Subcutaneous nodules of cysticercosis as a sign of asymptomatic neurocysticercosis in an HIV positive patient.

Cysticercosis is caused by the hematogenous dissemination of the larval form (cysticercus) of Taenia solium. It can affect any organ or tissue in the body but commonly affects the subcutaneous tissue,...

Clinical Trials [7539 Associated Clinical Trials listed on BioPortfolio]

Treatment of Patients With Active Neurocysticercosis in Eastern Africa

This multi-centre prospective cohort study of symptomatic patients with active neurocysticercosis (NCC) aims to identify factors related to treatment success of anthelmintic therapy. ...

Treatment of Peri-calcification Edema in Neurocysticercosis (NCC)

Three-arm open, randomized comparative study of acetazolamide, dexamethasone, or no additional treatment to evaluate decrease in peri-calcification edema in neurocysticercosis

Corticosteroids to Reduce Frequency of Seizures in Neurocysticercosis Patients

The purpose of this study is to determine whether a short course of increased corticosteroid dosing with tapered dosing decreases seizure frequency as compared to standard corticosteroid d...

Sub Arachnoid Neurocysticercosis Treatment Outcome (SANTO)

Taenia solium neurocysticercosis (NCC) is a parasitic infection causing much neurological disease in most of the world. When parasites locate in the cavities around the brain (subarachnoid...

Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis

OBJECTIVES: I. Determine the effect of antiparasitic treatment with albendazole on the severity and duration of epilepsy due to neurocysticercosis. II. Determine the effect of a short ...

Medical and Biotech [MESH] Definitions

An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.

A family of transcription factors that are induced by GROWTH FACTORS and contain a highly conserved DNA-binding domain composed of three ZINC FINGER MOTIFS.

Infection of the brain, spinal cord, or perimeningeal structures with the larval forms of the genus TAENIA (primarily T. solium in humans). Lesions formed by the organism are referred to as cysticerci. The infection may be subacute or chronic, and the severity of symptoms depends on the severity of the host immune response and the location and number of lesions. SEIZURES represent the most common clinical manifestation although focal neurologic deficits may occur. (From Joynt, Clinical Neurology, 1998, Ch27, pp46-50)

These growth factors comprise a family of hematopoietic regulators with biological specificities defined by their ability to support proliferation and differentiation of blood cells of different lineages. ERYTHROPOIETIN and the COLONY-STIMULATING FACTORS belong to this family. Some of these factors have been studied and used in the treatment of chemotherapy-induced neutropenia, myelodysplastic syndromes, and bone marrow failure syndromes.

Activating transcription factors were originally identified as DNA-BINDING PROTEINS that interact with early promoters from ADENOVIRUSES. They are a family of basic leucine zipper transcription factors that bind to the consensus site TGACGTCA of the cyclic AMP response element, and are closely related to CYCLIC AMP-RESPONSIVE DNA-BINDING PROTEIN.

Quick Search


DeepDyve research library

Searches Linking to this Article